Advent International has entered an agreement to purchase Sanofi’s European generics business Zentiva for €1.9bn ($2.2bn).

Advent intends to invest in Zentiva’s operations, production facilities and its research and development (R&D) pipeline, post transaction.

The acquisition will be closed in the fourth quarter of 2018, subject to customary closing conditions.

Based in the US, Advent International is a private equity firm, while Zentiva is a Czech Republic-based provider of generic medicines for various therapeutic areas.

The acquisition will enable the acquirer company to provide patients with high-quality treatments at lower cost.

“Eli Lilly has completed the acquisition of ARMO BioSciences for a cash consideration of more than $1.6bn.”

Eli Lilly has completed the acquisition of ARMO BioSciences for a cash consideration of more than $1.6bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company signed an agreement to purchase all outstanding shares of ARMO at $50 a share in May this year.

Based in the US, Eli Lilly is a pharmaceutical company that provides drugs for cancer treatment, while ARMO, also based in the US, is an immuno-oncology firm that develops drug candidates to treat diseases related to immune system.

The acquisition of ARMO will be a complementary addition to Eli Lilly’s oncology portfolio.